Age – Talk Bio

CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s

1 week ago talkbio0Tagged 50–59, Adult, Age, Arexvy, broaden, Centers for Disease Control and Prevention (U.S.), Chronic Condition, Recommendation, Respiratory syncytial virus, Severe (severity modifier), Vaccines

Adult, Respiratory syncytial virus, Centers for Disease Control and Prevention (U.S.), Vaccines, Recommendation, Age, Arexvy, Chronic Condition, Severe (severity modifier), 50–59, broaden

GSK’s RSV Vaccine Wins Expected Expansion into At-Risk Adults Aged 50-59

11 months ago talkbio0Tagged Adult, Age, Approved, Arexvy, Asthma, Chronic Obstructive Airway Disease, Diabetes, Heart failure, Increased, medical conditions, Respiratory syncytial virus, Respiratory Tract Diseases, Risk, SmithKline Beecham, United States Food and Drug Administration, Vaccines

GSK, RSV vaccine, Arexvy, FDA approval, adults aged 50-59, increased risk, respiratory syncytial virus, lower respiratory tract disease, medical conditions, chronic obstructive pulmonary disease, asthma, heart failure, diabetes.